

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

*(stock code: 950)*

### **SUPPLEMENTAL ANNOUNCEMENT CONNECTED TRANSACTION AND DISCLOSEABLE TRANSACTION**

Reference is made to the announcement made by Lee's Pharmaceutical Holdings Limited (the "**Company**") on 12 August 2013 for connected transaction and discloseable transaction (the "**Transaction Announcement**"). Terms defined in this announcement shall have the same meanings as those defined in the Transaction Announcement unless the context otherwise requires.

The Company hereby provides additional information as follows:–

#### **The Maximum Of Liability On The Indemnity**

As disclosed in the Transaction Announcement, the Indemnity is provided by CCF and the Company. The maximum liability of CCF and the Company under the Indemnity shall not exceed the amount equal to the proceeds respectively paid by each of LAV and CDIB in connection with the sale and purchase of the Series B Shares (i.e. US\$4,500,000 for LAV and US\$2,000,000 for CDIB).

The maximum liabilities under the Indemnity were determined after arm's length negotiation between the relevant parties to the Transaction Documents with reference to the amount paid by each of LAV and CDIB for the sale and purchase of the Series B Shares.

\* *for identification purpose only*

## **Further information on CVie Therapeutics and LAV**

Apart from the unaudited net loss of CVie Therapeutics (both before and after taxation) for the six months period ended 30 June 2013 as disclosed in the Transaction Announcement, the audited net loss of CVie Therapeutics (both before and after taxation) for the period from the date of incorporation (i.e. 5 April 2012) to 31 December 2012 (both before and after taxation) were the same and were HK\$1,262,203.

The net asset value of CVie Therapeutics under the unaudited management account of CVie Therapeutics as at 30 June 2013 was HK\$77,234,000.

Apart from the information in connection with LAV as disclosed in the Transaction Announcement, LAV is an investment holding company.

All other information set out in the Transaction Announcement remains unchanged.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 16 August 2013

*As at the date thereof, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors; Mr. Mauro Bove is non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*